Collins Stewart Starts Anthera Pharma (ANTH) at Buy; Rare Risk/Reward Opportunity
Tweet
Share
E-mailGet Alerts ANTH Hot Sheet
Price: $0.00 --0%
Rating Summary:
8 Buy, 3 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Rating Summary:
8 Buy, 3 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Join SI Premium – FREE
Collins Stewart initiates coverage on Anthera Pharma (NASDAQ: ANTH) with a Buy. PT $20.00.
Collins analyst says, "ANTH has two value-driving assets in varespladib (P3) for acute coronary syndrome (ACS) and blisibimod (bmod; P2b) for lupus, with data from both studies expected in 2Q12. While we are cautious on the likelihood of success for the varespladib VISTA-16 trial (we handicap it at 35%), primarily due to study design concerns, a positive outcome could propel varespladib to standard of care. However, if VISTA-16 fails, the downside is likely mitigated by bmod given its validated mechanism of action. While bmod will compete with Benlysta in an evolving lupus market, its SC administration should drive uptake as could other potential points of differentiation. We model for varespladib and bmod WW peak revenue of $1.7B and $500M, respectively, resulting in revenue to ANTH of $400M and $100M, given both assets will likely be partnered."
For an analyst ratings summary and ratings history on Anthera Pharma click here. For more ratings news on Anthera Pharma click here.
Shares of Anthera Pharma closed at $5.79 yesterday.
Collins analyst says, "ANTH has two value-driving assets in varespladib (P3) for acute coronary syndrome (ACS) and blisibimod (bmod; P2b) for lupus, with data from both studies expected in 2Q12. While we are cautious on the likelihood of success for the varespladib VISTA-16 trial (we handicap it at 35%), primarily due to study design concerns, a positive outcome could propel varespladib to standard of care. However, if VISTA-16 fails, the downside is likely mitigated by bmod given its validated mechanism of action. While bmod will compete with Benlysta in an evolving lupus market, its SC administration should drive uptake as could other potential points of differentiation. We model for varespladib and bmod WW peak revenue of $1.7B and $500M, respectively, resulting in revenue to ANTH of $400M and $100M, given both assets will likely be partnered."
For an analyst ratings summary and ratings history on Anthera Pharma click here. For more ratings news on Anthera Pharma click here.
Shares of Anthera Pharma closed at $5.79 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Scotiabank Starts Tenable (TENB) at Sector Perform
- Scotiabank Starts Qualys (QLYS) at Sector Perform
- Goldman Sachs Starts Victoria's Secret (VSCO) at Sell, 'Tough macro and ongoing competitive pressures'
Create E-mail Alert Related Categories
New CoverageRelated Entities
Collins StewartSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
